2020
Use of prophylactic cranial irradiation in patients with extensive-stage small cell lung cancer receiving immunotherapy.
Yang D, Jairam V, Park H, Decker R, Chiang A, Gross C, Yu J. Use of prophylactic cranial irradiation in patients with extensive-stage small cell lung cancer receiving immunotherapy. Journal Of Clinical Oncology 2020, 38: e19309-e19309. DOI: 10.1200/jco.2020.38.15_suppl.e19309.Peer-Reviewed Original ResearchExtensive-stage small-cell lung cancerFirst-line chemoSmall cell lung cancerES-SCLC patientsCell lung cancerSurvival benefitIO patientsLung cancerStudy periodFirst-line atezolizumabInitial systemic therapyProphylactic cranial irradiationFirst-line chemotherapyRetrospective cohort analysisContemporary practice patternsDe-identified databaseUse of PCIEffectiveness of PCICHEMO patientsCranial irradiationIO therapyPCI useSystemic therapyMRI surveillancePractice patterns
2019
Radiation therapy treatment facility and overall survival in the adjuvant setting for locally advanced head and neck squamous cell carcinoma
Lee NCJ, Kelly JR, An Y, Park HS, Judson BL, Burtness BA, Husain ZA. Radiation therapy treatment facility and overall survival in the adjuvant setting for locally advanced head and neck squamous cell carcinoma. Cancer 2019, 125: 2018-2026. PMID: 30748002, PMCID: PMC6541535, DOI: 10.1002/cncr.32001.Peer-Reviewed Original ResearchConceptsHigh-volume surgical facilitiesPostoperative radiation therapyNeck squamous cell carcinomaSquamous cell carcinomaOverall survivalSurvival benefitCell carcinomaSurgical facilitiesPropensity score-matched cohortAnnual case volumeDefinitive surgeryAdvanced headOS improvementImproved outcomesRadiation therapyCase volumeOral cavityPatientsReduced hazardMultivariate analysisSurgeryInvasive HNSCCCarcinomaSurvivalTreatment
2018
Adjuvant Chemotherapy Is Associated With Improved Survival for Late‐Stage Salivary Squamous Cell Carcinoma
Cheraghlou S, Schettino A, Zogg CK, Otremba MD, Bhatia A, Park HS, Osborn HA, Mehra S, Yarbrough WG, Judson BL. Adjuvant Chemotherapy Is Associated With Improved Survival for Late‐Stage Salivary Squamous Cell Carcinoma. The Laryngoscope 2018, 129: 883-889. PMID: 30151947, DOI: 10.1002/lary.27444.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, Squamous CellChemoradiotherapy, AdjuvantChemotherapy, AdjuvantCombined Modality TherapyFemaleHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasm StagingPropensity ScoreProportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesSalivary Gland NeoplasmsSurvival RateTreatment OutcomeConceptsLate-stage patientsSquamous cell carcinomaAdjuvant radiotherapyAdjuvant therapyAdjuvant chemoradiotherapyAdjuvant chemotherapyImproved survivalCell carcinomaImproved long-term survivalCox survival regressionPrimary cutaneous malignanciesUnique disease entityAddition of chemotherapyNational Cancer DatabaseEarly-stage diseaseFive-year survivalEarly-stage patientsKaplan-Meier analysisParotid gland cancerLate stage groupLong-term survivalSurvival benefitCutaneous malignanciesPoor prognosisRetrospective study
2016
The Association Between Evaluation at Academic Centers and the Likelihood of Expectant Management in Low-risk Prostate Cancer
Lester-Coll NH, Park HS, Rutter CE, Corso CD, Mancini BR, Yeboa DN, Kim SP, Gross CP, Yu JB. The Association Between Evaluation at Academic Centers and the Likelihood of Expectant Management in Low-risk Prostate Cancer. Urology 2016, 96: 128-135. PMID: 27392652, DOI: 10.1016/j.urology.2016.06.042.Peer-Reviewed Original ResearchConceptsLow-risk prostate cancerCancer center typeExpectant managementProstate cancerAcademic centersDefinitive treatmentNational Cancer Data BaseHierarchical mixed-effects logistic regression modelsMixed effects logistic regression modelsEffects logistic regression modelsLogistic regression modelsCommunity centersSurvival benefitActive surveillanceCenter typeRetrospective analysisLarge cohortTreatment selectionPertinent covariatesCancerInterfacility variationMenFacility typeFurther investigationRegression models
2015
Survival Benefit of Concurrent Chemoradiation Therapy for Unresected Glioblastoma Multiforme in the Temozolomide Era
Kole A, Yeboa D, Rutter C, Lester-Coll N, Corso C, Mancini B, Bindra R, Yu J, Park H. Survival Benefit of Concurrent Chemoradiation Therapy for Unresected Glioblastoma Multiforme in the Temozolomide Era. International Journal Of Radiation Oncology • Biology • Physics 2015, 93: e64. DOI: 10.1016/j.ijrobp.2015.07.706.Peer-Reviewed Original ResearchRole of Chemoradiotherapy in Elderly Patients With Limited-Stage Small-Cell Lung Cancer
Corso CD, Rutter CE, Park HS, Lester-Coll NH, Kim AW, Wilson LD, Husain ZA, Lilenbaum RC, Yu JB, Decker RH. Role of Chemoradiotherapy in Elderly Patients With Limited-Stage Small-Cell Lung Cancer. Journal Of Clinical Oncology 2015, 33: 4240-4246. PMID: 26481366, PMCID: PMC4678178, DOI: 10.1200/jco.2015.62.4270.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapyComorbidityDatabases, FactualFemaleHumansKaplan-Meier EstimateLung NeoplasmsMaleNeoplasm StagingOdds RatioPropensity ScoreRetrospective StudiesSex FactorsSmall Cell Lung CarcinomaTime FactorsTreatment OutcomeUnited StatesConceptsElderly patientsOverall survivalSurvival benefitLung cancerLimited-stage small cell lung cancerCancer clinical stage IClinical stage III diseaseNational Cancer Data BaseCox proportional hazards regressionPropensity scoreSmall cell lung cancerLarge population-based cohortLimited-Stage SmallRole of chemoradiotherapyClinical stage IStage III diseaseUse of chemoradiotherapyCell lung cancerPopulation-based cohortProportional hazards regressionLog-rank testMixed-effects logistic regressionLarge national databaseOS advantageSequential chemoradiotherapy
2014
Prophylactic Cranial Irradiation for Patients With Locally Advanced Non–Small-Cell Lung Cancer at High Risk for Brain Metastases
Park HS, Decker RH, Wilson LD, Yu JB. Prophylactic Cranial Irradiation for Patients With Locally Advanced Non–Small-Cell Lung Cancer at High Risk for Brain Metastases. Clinical Lung Cancer 2014, 16: 292-297. PMID: 25499149, DOI: 10.1016/j.cllc.2014.11.005.Peer-Reviewed Original ResearchConceptsProphylactic cranial irradiationLA-NSCLC patientsSequential landmark analysesCell lung cancerBrain metastasesHigh riskCranial irradiationSurvival benefitLung cancerLandmark analysisEffect of PCICox proportional hazards regressionNon-PCI patientsOverall survival benefitEnd Results (SEER) databaseHigh-risk patientsStage III NSCLCGroup of patientsProportional hazards regressionLog-rank testSignificant survival differenceImmortal time biasPopulation-based analysisAdult patientsOnly patients